Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07526428 · ClinicalTrials.gov registry record · NA
Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment
A NA study, sponsored by Sonova.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT07526428: Clinical Trial NA study, sponsored by Sonova.
NCT07526428 is a NA study that was terminated before completion, run by Sonova. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07526428, a NA study, was terminated before completion, sponsored by Sonova.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are: Do participants correctly identify significantly more words on the AZBio Sentence Test when using Phonak's DNN NR feature than when using Competitor device A in a lab setting? Do participants subjectively rate the speech clarity, ease of listening, and listening confidence higher when using Phonak's DNN feature than when using Competitor device A in both a lab setting and a real-world cafe setting? Do participants have an overall preference for the Phonak device over the Competitor device A in a real-world cafe setting? Participants will be fit with both the Phonak device and a Competitor device A in the lab. They will be given the AZBio Sentence test and repeat as many words as they can in a simulated noisy environment. Following the lab visit, participants will meet in a group with three other conversation partners in a real-world setting and asked to complete subjective questionnaires during the visit.
Primary Outcome
A validated speech perception test consisting of 25 different lists of sentences. Sentences are presented via a loudspeaker at a pre-determined level and the number of words correctly repeated are calculated into a percenteage. The higher the percentage, the better the participant's speech perception.
Interventions
- DEVICE Phonak Audeo Infinio Hearing Aid
- DEVICE Competitor Device A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2026-04-09 |
| Est. Completion | 2026-04-19 |
| Phase | NA |
Why NCT07526428 stopped before completion
NCT07526428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Phonak Audeo Infinio Hearing Aid is the first listed.
NCT07526428 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07526428 about?
NCT07526428 is a clinical study titled "Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment". The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are: Do participants correctly identify significantly more words on the AZBio Sentence Test when ...
What is the current status of trial NCT07526428?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2026-04-09. Estimated completion is 2026-04-19.
What interventions are being tested in trial NCT07526428?
The interventions under investigation include: Phonak Audeo Infinio Hearing Aid (DEVICE), Competitor Device A (DEVICE).
Who is sponsoring clinical trial NCT07526428?
This trial is sponsored by Sonova, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07526428's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI